Australia - angielski - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - droperidol, quantity: 2.5 mg/ml - injection, solution - excipient ingredients: tartaric acid; water for injections; sodium hydroxide; mannitol - anaesthesia droperidol solution for injection is indicated to produce tranquillisation and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures; for premedication, induction, and as an adjunct in the maintenance of general and regional anaesthesia; in neuroleptanalgesia in which droperidol solution for injection is given concurrently with a narcotic analgesic, to aid in producing tranquillity and decreasing anxiety and pain.,psychiatry the management of severe agitation, hyperactivity, or aggressiveness in psychotic disorders, including schizophrenic reaction and the manic type of manic depressive illness, or in disturbed states, such as some types of acute brain syndrome and in nonpsychotic acute excitation states.

Unia Europejska - angielski - EMA (European Medicines Agency)

ge healthcare b.v. - ioflupane (123l) - tomography, emission-computed, single-photon; lewy body disease; parkinson disease; alzheimer disease - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.datscan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. datscan is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy.in adult patients, to help differentiate probable dementia with lewy bodies from alzheimer’s disease. datscan is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Unia Europejska - angielski - EMA (European Medicines Agency)

cis bio international - ioflupane (123l) - radionuclide imaging; dementia; movement disorders - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.striascan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. striascan is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy.in adult patients, to help differentiate probable dementia with lewy bodies from alzheimer’s disease. striascan is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Izrael - angielski - Ministry of Health

megapharm ltd - amantadine hemisulfate - film coated tablets - amantadine hemisulfate 100 mg - amantadine - parkinsonian syndromes:treatment of symptoms of parkinson’s disease such as rigor, tremor, hypokinesia and akinesia.

Izrael - angielski - Ministry of Health

megapharm ltd - amantadine hemisulfate - film coated tablets - amantadine hemisulfate 100 mg - amantadine - parkinsonian syndromes:treatment of symptoms of parkinson’s disease such as rigor, tremor, hypokinesia and akinesia.

Unia Europejska - angielski - EMA (European Medicines Agency)

pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy.in adult patients, to help differentiate probable dementia with lewy bodies from alzheimer’s disease. celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Kanada - angielski - Health Canada

merck frosst canada & cie, merck frosst canada & co. - benztropine mesylate - solution - 1mg - benztropine mesylate 1mg - anticholinergic agents

Kanada - angielski - Health Canada

merck frosst canada & cie, merck frosst canada & co. - benztropine mesylate - tablet - 2mg - benztropine mesylate 2mg - anticholinergic agents

Kanada - angielski - Health Canada

pendopharm division of pharmascience inc - benztropine mesylate - tablet - 2mg - benztropine mesylate 2mg - anticholinergic agents

Kanada - angielski - Health Canada

icn canada ltd. - benztropine mesylate - tablet - 2mg - benztropine mesylate 2mg - anticholinergic agents